These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 39008024)

  • 1. Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing Reports.
    Mahadevan U; Levy G; Gensler L; Ali M; Lacerda AP; Wegrzyn L; Palac H; Bhutani-Jacques T; Long M; Clowse MEB; Kimball AB; Chambers C; Scialli AR
    Drug Saf; 2024 Oct; 47(10):1039-1049. PubMed ID: 39008024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience.
    Vukusic S; Coyle PK; Jurgensen S; Truffinet P; Benamor M; Afsar S; Purvis A; Poole EM; Chambers C
    Mult Scler; 2020 Jun; 26(7):829-836. PubMed ID: 30968734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exposure to Infliximab During Pregnancy: Post-Marketing Experience.
    Geldhof A; Slater J; Clark M; Chandran U; Coppola D
    Drug Saf; 2020 Feb; 43(2):147-161. PubMed ID: 31677004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
    Nader A; Stodtmann S; Friedel A; Mohamed MF; Othman AA
    J Clin Pharmacol; 2020 Apr; 60(4):528-539. PubMed ID: 31701537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data.
    Hoeltzenbein M; Beck E; Rajwanshi R; Gøtestam Skorpen C; Berber E; Schaefer C; Østensen M
    Semin Arthritis Rheum; 2016 Oct; 46(2):238-245. PubMed ID: 27346577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.
    Giovannoni G; Galazka A; Schick R; Leist T; Comi G; Montalban X; Damian D; Dangond F; Cook S
    Drug Saf; 2020 Jul; 43(7):635-643. PubMed ID: 32447743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes.
    Coppola D; Russo LJ; Kwarta RF; Varughese R; Schmider J
    Drug Saf; 2007; 30(3):247-64. PubMed ID: 17343431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations.
    Charlton RA; Weil JG; Cunnington MC; Ray S; de Vries CS
    Drug Saf; 2011 Feb; 34(2):157-71. PubMed ID: 21247222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lacosamide and pregnancy: Data from spontaneous and solicited reports.
    Perucca P; Bourikas D; Voinescu PE; Vadlamudi L; Chellun D; Kumke T; Werhahn KJ; Schmitz B
    Epilepsia; 2024 May; 65(5):1275-1284. PubMed ID: 38411300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy Outcomes in Patients Exposed to OnabotulinumtoxinA Treatment: A Cumulative 29-Year Safety Update.
    Brin MF; Kirby RS; Slavotinek A; Adams AM; Parker L; Ukah A; Radulian L; Elmore MRP; Yedigarova L; Yushmanova I
    Neurology; 2023 Jul; 101(2):e103-e113. PubMed ID: 37137724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database.
    Clowse MEB; Scheuerle AE; Chambers C; Afzali A; Kimball AB; Cush JJ; Cooney M; Shaughnessy L; Vanderkelen M; Förger F
    Arthritis Rheumatol; 2018 Sep; 70(9):1399-1407. PubMed ID: 29623679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillance.
    MacDonald SC; Cohen JM; Panchaud A; McElrath TF; Huybrechts KF; Hernández-Díaz S
    Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1211-1221. PubMed ID: 31328328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
    Burmester GR; Stigler J; Rubbert-Roth A; Tanaka Y; Azevedo VF; Coombs D; Lagunes I; Lippe R; Wung P; Gensler LS
    Rheumatol Ther; 2024 Jun; 11(3):737-753. PubMed ID: 38683479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Review with Meta-analysis: Efficacy and Safety of Upadacitinib in Managing Moderate-to-Severe Crohn's Disease and Ulcerative Colitis.
    Niu C; Zhang J; Napel M; Boppana LKT; Anas H; Jadhav N; Dunnigan K; Okolo PI
    Clin Drug Investig; 2024 Jun; 44(6):371-385. PubMed ID: 38777970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience.
    Gold R; Phillips JT; Havrdova E; Bar-Or A; Kappos L; Kim N; Thullen T; Valencia P; Oliva L; Novas M; Li J; Sweetser MT; Kurukulasuriya N; Viglietta V; Fox RJ
    Neurol Ther; 2015 Dec; 4(2):93-104. PubMed ID: 26662361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
    Silverberg JI; Gooderham MJ; Paller AS; Deleuran M; Bunick CG; Gold LFS; Hijnen D; Calimlim BM; Lee WJ; Teixeira HD; Hu X; Zhang S; Yang Y; Grada A; Platt AM; Thaçi D
    Am J Clin Dermatol; 2024 May; 25(3):485-496. PubMed ID: 38528257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials.
    Mysler E; Burmester GR; Saffore CD; Liu J; Wegrzyn L; Yang C; Betts KA; Wang Y; Irvine AD; Panaccione R
    Adv Ther; 2024 Feb; 41(2):567-597. PubMed ID: 38169057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry.
    Hellwig K; Geissbuehler Y; Sabidó M; Popescu C; Adamo A; Klinger J; Ornoy A; Huppke P;
    J Neurol; 2020 Jun; 267(6):1715-1723. PubMed ID: 32100126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports.
    Petri M; Landy H; Clowse MEB; Gemzoe K; Khamashta M; Kurtinecz M; Levy RA; Liu A; Marino R; Meizlik P; Pimenta JM; Sumner K; Tilson H; Connolly MB; Wurst K; Harris J; Quasny H; Juliao P; Roth DA
    Ann Rheum Dis; 2023 Feb; 82(2):217-225. PubMed ID: 36198440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports.
    Goldman A; Galper BL; Druyan A; Grossman C; Sharif K; Shechtman L; Moshkovits Y; Lahat A; Ben-Zvi I
    Semin Arthritis Rheum; 2024 Aug; 67():152461. PubMed ID: 38772185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.